文献速递头颈部肿瘤放疗

影像学结外侵犯对下咽癌根治性放化疗患者的预后价值

Prognostic value of radiologic extranodal extension in patients with hypopharyngeal cancer treated with primary chemoradiation.
PubMed 文献 · Radiother Oncol · 2020-12-30

该研究基于2005至2014年癌症登记数据,纳入355例接受根治性放疗的临床N1-3期下咽癌患者,由两位放射科医生判读影像学结外侵犯(rENE)。结果显示rENE患者3年总生存和无复发生存均较低,rENE是RFS的独立不良预后因素,且不受N分期影响。

要点

  • rENE与下咽癌根治性放化疗后较差的3年OS和RFS相关。
  • 多因素分析中rENE是RFS的独立不良预后因素,但与OS独立相关的是临床T4或N3。
  • N1/2无rENE组3年RFS为55.8%,显著高于N1/2有rENE组41.0%和N3组29.3%。

核心结论

  • rENE是接受根治性放化疗的下咽癌患者生存的不良预后因素,与较差RFS相关且不受N分期影响,未来或可作为临床ENE的 staging 标准。

研究设计与样本

  • 回顾性分析2005至2014年癌症登记数据,纳入355例临床N1-3期(AJCC第7版)接受放疗的下咽癌患者,排除M1及同时/异时性癌。
  • 由两位放射科医生复习分期影像,rENE定义为侵犯邻近脂肪/肌肉、淋巴结表面不规则或包膜强化不规则。

主要发现

  • rENE患者3年OS和RFS较低;单因素分析显示临床T4或N3、总分期IV期及rENE与OS和RFS相关。
  • 多因素分析中临床T4或N3与较差OS相关,临床T4或N3及rENE是较差RFS的独立预测因素。
  • 分组1(N1/2无rENE)、组2(N1/2有rENE)、组3(N3有无rENE)的3年RFS分别为55.8%、41.0%、29.3%,组1显著高于其他两组。

关键数值与推荐

  • rENE定义为影像上侵犯邻近脂肪/肌肉、淋巴结表面不规则或包膜强化不规则。
  • 分组1为N1/2无rENE,组2为N1/2有rENE,组3为N3有无rENE;3年RFS分别为55.8%、41.0%、29.3%。

临床怎么用

  • 对下咽癌根治性放化疗患者,应评估影像学rENE以辅助预后分层,rENE阳性者RFS较差。
  • rENE可与N分期结合用于风险分组,未来分期系统可考虑将其纳入临床ENE标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: We aimed to evaluate the prognostic value of radiologic extranodal extension (rENE) in patients with hypopharyngeal cancer (HPC) treated with primary chemoradiation. MATERIALS AND METHODS: Cancer registry data were reviewed from 2005 to 2014. Inclusion criteria included HPC, clinical N1-3 disease (AJCC staging system, 7th edition), and receiving radiotherapy. Patients with M1 diseaseor with synchronous/metachronous cancer were excluded. Staging images were reviewed by two radiologists. rENE was defined as infiltration of adjacent fat/muscles, irregular nodal surface, or irregular capsular enhancement. Clinical stage, rENE status, and clinical outcome were analyzed. RESULTS: Overall, 355 patients were included. Patients with rENE had lower 3-year overall survival (OS) and recurrence-free survival (RFS) rates. Univariate analysis showed that clinical T4 or N3 stage, overall stage IV, and rENE correlated with OS and RFS. In multivariate analysis, clinical T4 or N3 stage correlated with poor OS, while clinical T4 or N3 stage and rENE were independent predictors of poor RFS. N1/2 without rENE was designated as Group 1, N1/2 with rENE as Group 2, and N3 with/without rENE as Group 3. The 3-year RFS rates in Groups 1, 2, and 3 were 55.8%, 41.0%, and 29.3%, respectively. The 3-year RFS rate in Group 1 was significantly higher than that in the other two groups. CONCLUSIONS: rENE is an adverse prognostic factor for survival in patients with HPC treated with primary chemoradiation. It correlated with inferior RFS regardless of N stage. rENE may be used as a criterion for clinical ENE in future staging systems.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Fan KH, Yeh CH, Hung SP, et al. Prognostic value of radiologic extranodal extension in patients with hypopharyngeal cancer treated with primary chemoradiation. Radiother Oncol. 2020. PMID: 33385465. doi:10.1016/j.radonc.2020.12.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。